You are here

Bioiberica releases new research data at OARSI

11 Nov 2010
  • On 23 September, Brussels held the World Congress on Osteoarthritis, hosted by the OARSI. Bioiberica was there to present the results of a range of studies conducted over the past year. In addition, we hosted two symposia on osteoarthritis:

In a presentation titled Personalized medicine: new challenge in osteoarthritis, Bioiberica explained its new developments and research findings in personalized medicine for osteoarthritis.

Speakers included Professor Henrotin, of the University of Liege, who talked about the latest advances in osteoarthritis biomarkers, and Professor Guillen, who reported on his progress in cell therapy research, specifically regarding chondrocyte transplant.

Also presented was the Arthrosischip, the first osteoarthritis prognosis kit based on DNA analysis.

As usual in recent years, Bioiberica hosted a symposium on the efficacy of chondroitin sulphate for osteoarthritis treatment. In that symposium, titled Structure Disease Modification in OA: Targeting the Whole Joint, we released new data demonstrating the DMOAD efficacy of CS and its clinical efficacy in structures altered by osteoarthritis.

In consonance with its commitment to research, Bioiberica also presented a number of studies in poster format:

The data from the study Anti-inflamatory activity and absorption of Hyal-Joint® were presented. This study indicates that Hyal-Joint® has anti-inflammatory effects and is well absorbed through the intestine.

Also, the study Effects of oral administration of Hyal-Joint® in 17 day rat developing type II collagen arthritis was presented. The results suggest that the use of Hyal-Joint® for the management of developing type II collagen arthritis in rats is safe and effective.

The data from the study Transdermal permeation of Hialsorb® under the effect of ultrasounds were also presented. This study demonstrates that therapeutic ultrasound increases the permeation of the glycosaminoglycans present in Hialsorb®, therefore topical application of the formulation is suitable for ultrasound transmission, to enhance the effects of physiotherapy.

Bioiberica was in Rome last June for The Annual European Congress of Rheumatology, EULAR 2010.

This November, Bioiberica shall be in Atlanta, United States, for the Annual Scientific Meeting of the American College of Rheumatology (ACR).